全文获取类型
收费全文 | 249628篇 |
免费 | 37745篇 |
国内免费 | 2718篇 |
专业分类
耳鼻咽喉 | 6226篇 |
儿科学 | 7811篇 |
妇产科学 | 4007篇 |
基础医学 | 17352篇 |
口腔科学 | 3625篇 |
临床医学 | 36651篇 |
内科学 | 67735篇 |
皮肤病学 | 9164篇 |
神经病学 | 25169篇 |
特种医学 | 10351篇 |
外国民族医学 | 6篇 |
外科学 | 54747篇 |
综合类 | 1481篇 |
现状与发展 | 72篇 |
一般理论 | 73篇 |
预防医学 | 14735篇 |
眼科学 | 4997篇 |
药学 | 7762篇 |
中国医学 | 117篇 |
肿瘤学 | 18010篇 |
出版年
2024年 | 734篇 |
2023年 | 5246篇 |
2022年 | 2224篇 |
2021年 | 5109篇 |
2020年 | 7203篇 |
2019年 | 4039篇 |
2018年 | 9616篇 |
2017年 | 8940篇 |
2016年 | 10328篇 |
2015年 | 10663篇 |
2014年 | 18458篇 |
2013年 | 19588篇 |
2012年 | 11897篇 |
2011年 | 11964篇 |
2010年 | 14041篇 |
2009年 | 17544篇 |
2008年 | 11508篇 |
2007年 | 10262篇 |
2006年 | 12237篇 |
2005年 | 9496篇 |
2004年 | 8413篇 |
2003年 | 6795篇 |
2002年 | 6842篇 |
2001年 | 5580篇 |
2000年 | 4732篇 |
1999年 | 4777篇 |
1998年 | 4785篇 |
1997年 | 4399篇 |
1996年 | 4107篇 |
1995年 | 3962篇 |
1994年 | 2606篇 |
1993年 | 2166篇 |
1992年 | 2507篇 |
1991年 | 2452篇 |
1990年 | 2055篇 |
1989年 | 2132篇 |
1988年 | 1867篇 |
1987年 | 1650篇 |
1986年 | 1708篇 |
1985年 | 1534篇 |
1984年 | 1213篇 |
1983年 | 1094篇 |
1982年 | 1057篇 |
1981年 | 845篇 |
1980年 | 751篇 |
1979年 | 824篇 |
1978年 | 730篇 |
1977年 | 766篇 |
1975年 | 606篇 |
1972年 | 609篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
Martin Lepage Karine Sergerie Marc Pelletier Philippe-Olivier Harvey 《Revue canadienne de psychiatrie》2007,52(11):702-709
Much of the research on episodic memory in schizophrenia spectrum disorders has focused on memory deficits and how they relate to clinical measures such as outcome. Memory bias refers to the modulatory influence that state or trait psychopathology may exert on memory performance for specific categories of stimuli, often emotional in nature. For example, subjects suffering from depression frequently have better memory for negative stimuli than for neutral or positive ones. This dimension of memory function has received only scant attention in schizophrenia research but could provide fresh new insights into the relation between symptoms and neurocognition. This paper reviews the studies that have explored memory biases in individuals with schizophrenia. With respect to positive symptoms, we examine studies that have explored the link between persecutory delusions and memory bias for threatening information and between psychosis and a memory bias toward external source memory. Although relatively few studies have examined negative symptoms, we also review preliminary evidence indicating that flat affect and anhedonia may lead to some specific emotional memory biases. Finally, we present recent findings from our group delineating the relation between emotional valence for faces and memory bias toward novelty and familiarity, both in schizophrenia patients and in healthy control subjects. A better understanding of the biasing effects of psychopathology on memory in schizophrenia (but also on other cognitive functions, such as attention, attribution, and so forth) may provide a stronger association between positive and negative symptoms and memory function. Memory measures sensitive to such biases may turn out to be stronger predictors of clinical and functional outcome. 相似文献
92.
93.
This review discusses treatment options for men with premature ejaculation (PE), a common sexual dysfunction characterized
by short ejaculatory latency, decreased sexual satisfaction, and distress. For a number of reasons, including embarrassment
and the belief that PE is a normal part of aging, that it has no effective treatment, or that it will resolve itself, few
men with PE seek treatment. Although several treatment options exist (eg, behavioral, cognitive, and sex therapy methods;
desensitizing drugs; off-label use of antidepressants, phosphodiesterase type 5 inhibitors, or à-blockers), the majority of
men with PE are not satisfied with their results. New pharmacologic drugs develped specifically for the treatment of PE are
undergoing evaluation in clinical trials. For example, recent clinical research studies have revealed on-demand administration
of one such drug, dapoxetine, which achieved significant improvements in ejaculatory latency, control over ejaculation, and
satisfaction with sexual intercourse. In addition, partners of men who received dapoxetine likewise reported improved satisfaction
with sexual intercourse. Future studies may reveal that integration of pharmacologic drugs with psychologic and/or behavioral
therapy techniques may be the optimal approach to the management of PE. PE is a treatable condition, and new drugs in development
may provide benefits over those available. 相似文献
94.
95.
96.
97.
98.
Prostatitis and male infertility are frequent disorders, and the role of prostatitis in male infertility has been under discussion for more than 30 years. Many researchers have shown relevant links between the two. Although a causal relationship has not been definitely demonstrated, increasing evidence shows that chronic prostatitis has a relevant negative impact on male fertility potential, at least in certain subgroups. In the following review, we focus on the present state of knowledge on the role of chronic prostatitis as an etiologic factor in male infertility. 相似文献
99.
J. Curtis Nickel MD 《Current Prostate Reports》2006,4(3):132-137
Medical therapy is currently the most popular treatment choice for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Because medical therapy of BPH-related LUTS is considered a life-long strategy, short- and long-term cost considerations should play a major role in therapeutic decision-making. The effectiveness in terms of long and short amelioration of symptoms, flow rate, and quality of life are well documented for 5α-blockers and 5α-reductase inhibitors as well as for the gold standard treatment for BPH, transurethral resection of the prostate and minimally invasive therapies. Short-and long-term safety concerns also are well documented for these various treatment options. On the contrary, short- and long-term costs have been less well studied and comparisons depend on the model or analyses undertaken in the few studies available. However, the economic studies based on prospective clinical trial data that have become available throughout the past several decades allow us to rationalize our use of α-blockers, 5α -reductase inhibitors, and combination therapy, taking into consideration age, severity of symptoms, prostate volume, prostate-specific antigen, and the differential response of the various medications (and combination) in selected patients. Based on current studies, 5α -blockers generally provide cost-effective therapy for most patients, whereas 5α-reductase therapy and combination therapy provide cost-effective treatment for patients with larger prostate glands or higher baseline prostate-specific antigen levels. 相似文献
100.